Kotzin served as Head of Clinical Immunology in the Department of Medicine and Director of the Autoimmunity Center of Excellence at the University of ColoradoHealth Sciences Center in Denver. Dr. During his 11 years at Amgen, he also served as Vice President of Medical Sciences, which encompassed early development, biomarker development, and clinical immunology. Kotzin served as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area at Amgen, directing the global development efforts for Amgen’s inflammation product candidates. Kotzin is currently Senior Vice President, Clinical Development at Nektar Therapeutics, Inc.
is a board-certified rheumatologist and internist with more than three decades of experience in the fields of inflammation and immunology in academia and industry. He is an author on over 85 publications and patents.īrian Kotzin, M.D. Fez earned his BSc in Chemistry and PhD in Organic Chemistry from Imperial College of Science, Technology & Medicine and completed his postdoctoral training at The University of Texas at Austin.
He has also led the search, scientific evaluation and execution of licensing deals and strategic partnerships, establishing numerous deals across a range of deal-types including dominant platform licenses for DNA-Encoded Library Technology and mRNA Display Technology. He has led discovery programs from inception to early clinical development, delivering eight preclinical development candidates of which three proceeded to clinical trials – including the discovery of the first-in-class small molecule MC4R agonist, MK-0493, for the treatment of obesity. He joined Merck in 1995 as Senior Research Chemist and rose to the rank of Executive Director of Chemistry before joining BD&L. Prior to joining the company, Fez was Director of Business Development and Licensing (BD&L) at Merck & Co., Inc. He is an author on over 50 publications and patents.įeroze (Fez) Ujjainwalla brings 26 years of experience in small molecule drug discovery to Terray. He completed his academic training after winning one of four Glaxo Wellcome Fellowships, conducting postdoctoral research at Stanford University. Adam earned his BSc in Chemistry (Henry Forth Prize) and his PhD in Organic Chemistry from the University of Nottingham. Adam directed new discoveries and nominations of 11 clinical candidates across a wide range of biological targets and therapeutic areas with high unmet medical needs, including the discovery of a first-in-class dual pharmacology bronchodilator, Batefenterol, for the treatment of COPD, which completed Phase 2b studies. He was also responsible for leading the Exploratory Science R&D effort to identify and nominate new projects for the company’s portfolio. With over 21 years of experience in small molecule drug discovery, he led preclinical research programs from inception to clinical candidate nomination, and supported IND-enabling studies and filings. Prior to joining Terray, Adam was Executive Director of Medicinal Chemistry at Theravance Biopharma.
0 kommentar(er)
